ME Therapeutics Inc., a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce the publication of their joint research on the role of G-CSF in breast and colorectal cancer in the peer-reviewed scientific journal, Cancer Research Communications. This journal aims to accelerate the pace of discovery and stimulate innovation in cancer science and medicine. The joint research was a collaboration between ME Therapeutics Inc. and Dr. Kenneth Harder’s laboratory at the University of British Columbia and was funded in part by an Innovation to Commercialization Competition Award from the Michael Smith Foundation for Health Research. Importantly, our publication describes the role tumor-derived G-CSF plays in suppressing immune responses against cancer and supports the company’s focus on G-CSF as a potentially important target in immuno oncology. A link to the publication can be found below.
https://aacrjournals.org/cancerrescommun/article/3/3/404/718631/Tumor-derived-GCSF-Alters-Tumor-and-Systemic
ME Therapeutics Inc.
Myeloid Enhancement (ME) Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-cancer immunity. For more information please visit www.metherapeutics.com and the Company’s profile on SEDAR+ at www.sedarplus.ca
ON BEHALF OF THE BOARD
“Salim Dhanji”
Dr. Salim Dhanji
Chief Executive Officer and Director
For further information, please contact:
Dr. Salim Dhanji
Telephone: (236) 516-7714
Forward Looking Statements
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s research plans, the intended outcomes of the research, the intended benefits and applications of the Company’s technology, and the Company’s plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, G-CSF proves to not play an important role in cancer, and that the Company’s business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
